231 related articles for article (PubMed ID: 14579081)
1. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study.
Verboom P; van Tinteren H; Hoekstra OS; Smit EF; van den Bergh JH; Schreurs AJ; Stallaert RA; van Velthoven PC; Comans EF; Diepenhorst FW; van Mourik JC; Postmus PE; Boers M; Grijseels EW; Teule GJ; Uyl-de Groot CA;
Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1444-9. PubMed ID: 14579081
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial.
van Tinteren H; Hoekstra OS; Smit EF; van den Bergh JH; Schreurs AJ; Stallaert RA; van Velthoven PC; Comans EF; Diepenhorst FW; Verboom P; van Mourik JC; Postmus PE; Boers M; Teule GJ
Lancet; 2002 Apr; 359(9315):1388-93. PubMed ID: 11978336
[TBL] [Abstract][Full Text] [Related]
3. Staging of non-small-cell lung cancer and application of FDG-PET. A cost modeling approach.
Verboom P; Herder GJ; Hoekstra OS; Smit EF; van den Bergh JH; van Velthoven PC; Grijseels EW
Int J Technol Assess Health Care; 2002; 18(3):576-85. PubMed ID: 12391950
[TBL] [Abstract][Full Text] [Related]
4. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
Weber WA; Dietlein M; Hellwig D; Kirsch CM; Schicha H; Schwaiger M
Nuklearmedizin; 2003 Aug; 42(4):135-44. PubMed ID: 12937692
[TBL] [Abstract][Full Text] [Related]
5. Practice, efficacy and cost of staging suspected non-small cell lung cancer: a retrospective study in two Dutch hospitals.
Herder GJ; Verboom P; Smit EF; van Velthoven PC; van den Bergh JH; Colder CD; van Mansom I; van Mourik JC; Postmus PE; Teule GJ; Hoekstra OS
Thorax; 2002 Jan; 57(1):11-4. PubMed ID: 11809983
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer.
Yap KK; Yap KS; Byrne AJ; Berlangieri SU; Poon A; Mitchell P; Knight SR; Clarke PC; Harris A; Tauro A; Rowe CC; Scott AM
Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1033-40. PubMed ID: 15875178
[TBL] [Abstract][Full Text] [Related]
7. Is FDG PET/CT cost-effective for pre-operation staging of potentially operative non-small cell lung cancer? - From Chinese healthcare system perspective.
Wang YT; Huang G
Eur J Radiol; 2012 Aug; 81(8):e903-9. PubMed ID: 22698711
[TBL] [Abstract][Full Text] [Related]
8. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
Gambhir SS; Hoh CK; Phelps ME; Madar I; Maddahi J
J Nucl Med; 1996 Sep; 37(9):1428-36. PubMed ID: 8790186
[TBL] [Abstract][Full Text] [Related]
9. Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors.
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Scheiderbauer J; Budach W; Kotzerke J; Bares R
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):54-9. PubMed ID: 16896660
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis.
Scott WJ; Shepherd J; Gambhir SS
Ann Thorac Surg; 1998 Dec; 66(6):1876-83; discussion 1883-5. PubMed ID: 9930463
[TBL] [Abstract][Full Text] [Related]
11. Medical economics of whole-body FDG PET in patients suspected of having non-small cell lung carcinoma--reassessment based on the revised Japanese national insurance reimbursement system.
Abe K; Kosuda S; Kusano S
Ann Nucl Med; 2003 Dec; 17(8):649-55. PubMed ID: 14971606
[TBL] [Abstract][Full Text] [Related]
12. Endoscopic ultrasound guided biopsy performed routinely in lung cancer staging spares futile thoracotomies: preliminary results from a randomised clinical trial.
Larsen SS; Vilmann P; Krasnik M; Dirksen A; Clementsen P; Maltbaek N; Lassen U; Skov BG; Jacobsen GK
Lung Cancer; 2005 Sep; 49(3):377-85. PubMed ID: 16102606
[TBL] [Abstract][Full Text] [Related]
13. Economic analyses on the use of positron emission tomography for the work-up of solitary pulmonary nodules and for staging patients with non-small-cell-lung-cancer in Italy.
Gugiatti A; Grimaldi A; Rossetti C; Lucignani G; De Marchis D; Borgonovi E; Fazio F
Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):49-61. PubMed ID: 15195004
[TBL] [Abstract][Full Text] [Related]
14. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer.
Schreyögg J; Weller J; Stargardt T; Herrmann K; Bluemel C; Dechow T; Glatting G; Krause BJ; Mottaghy F; Reske SN; Buck AK
J Nucl Med; 2010 Nov; 51(11):1668-75. PubMed ID: 21051648
[TBL] [Abstract][Full Text] [Related]
16. [Decision tree sensitivity analysis for cost-effectiveness of chest FDG-PET in patients with a pulmonary tumor (non-small cell carcinoma)].
Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
Kaku Igaku; 1998 Jul; 35(6):395-404. PubMed ID: 9753918
[TBL] [Abstract][Full Text] [Related]
17. Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan.
Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
Chest; 2000 Feb; 117(2):346-53. PubMed ID: 10669673
[TBL] [Abstract][Full Text] [Related]
18. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study.
Herder GJ; Kramer H; Hoekstra OS; Smit EF; Pruim J; van Tinteren H; Comans EF; Verboom P; Uyl-de Groot CA; Welling A; Paul MA; Boers M; Postmus PE; Teule GJ; Groen HJ;
J Clin Oncol; 2006 Apr; 24(12):1800-6. PubMed ID: 16567772
[TBL] [Abstract][Full Text] [Related]
19. The value of positron emission tomography in patients with non-small cell lung cancer.
Kee F; Erridge S; Bradbury I; Cairns K
Eur J Radiol; 2010 Jan; 73(1):50-8. PubMed ID: 19084367
[TBL] [Abstract][Full Text] [Related]
20. Decision-tree sensitivity analysis for cost-effectiveness of whole-body FDG PET in the management of patients with non-small-cell lung carcinoma in Japan.
Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
Ann Nucl Med; 2002 Jun; 16(4):263-71. PubMed ID: 12126096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
